Argenx (United States)

Argenx is a global immunology company developing antibody-based medicines for autoimmune diseases and cancer. Based in Boston, Massachusetts, the company developed VYVGART (efgartigimod), the first FDA-approved FcRn blocker for generalized myasthenia gravis (gMG). Argenx’s innovative ENHANZE technology platform creates next-generation treatments for immune-mediated disorders including chronic inflammatory demyelinating polyneuropathy (CIDP), pemphigus, and other severe autoimmune conditions.